Last quarter (Q4 2022), Faron Pharmaceuticals Oy's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, Faron Pharmaceuticals Oy's net income was €―. See Faron Pharmaceuticals Oy’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	€ 803.00K	-	€ 0.00	€ 0.00	€ 19.00K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	€ 803.00K	-	-	-	-
Operating Expense	-	€ 28.23M	€ 21.11M	€ 16.65M	€ 13.10M	€ 19.67M
Operating Income	-	€ -27.43M	€ -21.11M	€ -16.65M	€ -13.10M	€ -19.65M
Net Non Operating Interest Income Expense	-	€ -1.35M	€ 245.00K	€ -53.00K	€ -158.00K	€ -123.00K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	€ -28.73M	€ -21.18M	€ -16.93M	€ -13.25M	€ -20.08M
Tax Provision	-	-	€ 16.00K	€ 10.00K	€ 11.00K	€ 2.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ -28.73M	€ -21.19M	€ -16.94M	€ -13.26M	€ -20.09M
Basic EPS	-	€ -0.52	€ -0.42	€ -0.37	€ -0.31	€ -0.65
Diluted EPS	-	€ -0.52	€ -0.42	€ -0.37	€ -0.31	€ -0.65
Basic Average Shares	-	€ 55.23M	€ 50.72M	€ 45.71M	€ 35.53M	€ 30.75M
Diluted Average Shares	-	€ 55.23M	€ 50.72M	€ 45.71M	€ 35.53M	€ 30.75M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	€ 28.23M	€ -21.11M	€ 16.65M	€ 13.10M	€ 19.67M
Net Income From Continuing And Discontinued Operation	-	€ -28.73M	€ -21.19M	€ -16.94M	€ -13.26M	€ -20.09M
Normalized Income	-	€ -23.27M	€ -17.15M	€ -16.94M	€ -13.26M	€ -19.82M
Interest Expense	-	-	-	€ 149.00K	€ 156.00K	€ 121.00K
EBIT	-	€ -27.35M	€ -20.96M	€ -16.79M	€ -13.10M	€ -19.96M
EBITDA	-	€ -27.05M	€ -20.96M	€ -16.50M	€ -12.86M	€ -19.86M

Currency in EUR

Faron Pharmaceuticals Oy Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing